Bone Health

Latest News

Guy holding paper "FDA Approved" | Image credit: gustavofrazao -
FDA Approves First Denosumab Biosimilars

March 5th 2024

Sandoz’ Wyost/Jubbonti (denosumab-bddz) references Prolia and Xgeva and can be used to treat osteoporosis and hypercalcemia as well as prevent skeletal-related events associated with bone metastases from solid tumors.

Eye on pharma banner | Image credit: The Center for Biosimilars
Eye on Pharma: Coherus Offloads Cimerli; Celltrion Files for CT-P47; Alvotech Shares Denosumab Results

January 30th 2024

Eye on Pharma banner
Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars

January 11th 2024

blood stream
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

November 25th 2023

Eye on Pharma banner
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate

November 8th 2023

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.